Medifast outlines $270M–$300M 2026 revenue target as CEO transition and metabolic health focus drive execution (NYSE:MED)
MedifastMedifast(US:MED) Seeking Alpha·2026-02-17 23:25

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Medifast outlines $270M–$300M 2026 revenue target as CEO transition and metabolic health focus drive execution (NYSE:MED) - Reportify